CAMBRIDGE, Mass., March 27, 2017 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a leader in discovering and developing targeted kinase medicines for patients with genomically defined diseases, today announced that it will present on the discovery and development of BLU-285 and BLU-554 at the 2017 Annual Meeting of the American Association for Cancer Research, taking place April 1-5, 2017 in Washington D.C., and at the 253^rd American Chemical Society National Meeting & Exposition, taking place April 2-6, 2017 in San Francisco, CA.

Details of the presentations are as follows:

2017 Annual Meeting of the American Association for Cancer Research

Date & Time: Sunday, April 2, 2017 at 4:36 p.m. ET – 5:00 p.m. ET
Session Title: New Drugs on the Horizon 2
Presentation Title: BLU-285: A potent and highly selective inhibitor designed to treat malignancies driven by PDGFRα and KIT mutations
Location: East Salon A-B, Level 1, Walter E. Washington Convention Center

253^rd American Chemical Society National Meeting & Exposition

Date & Time: Wednesday, April 5, 2017 – 10:00 a.m. PT – 10:30 a.m. PT
Division Title: Division of Medicinal Chemistry
Session Title: First Time Disclosures
Paper ID: 2656485
Paper Title: Discovery and development of BLU-554: A potent, highly selective covalent inhibitor of Fibroblast Growth Factor Receptor 4 (FGFR4) in development for the targeted treatment of advanced Hepatocellular Carcinoma (HCC) patients with amplified and overexpressed FGF19
Location: 3002/3004 - Moscone Convention Center

Date & Time: Wednesday, April 5, 2017 – 3:30 p.m. PT – 4:00 p.m. PT
Division Title: Division of Medicinal Chemistry
Session Title: First Time Disclosures
Paper ID: 2656892
Paper Title: Discovery and development of BLU-285: A potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants
Location: 3002/3004 - Moscone Convention Center

Abstracts from presentations at the 253^rd American Chemical Society National Meeting & Exposition are available online on the conference website at: https://www.acs.org/content/acs/en/meetings/spring-2017.html.

About Blueprint Medicines

Blueprint Medicines is developing a new generation of targeted and potent kinase medicines to improve the lives of patients with genomically defined diseases. Its approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Blueprint Medicines is advancing four programs in clinical development for subsets of patients with gastrointestinal stromal tumors, hepatocellular carcinoma, systemic mastocytosis, non-small cell lung cancer, medullary thyroid cancer and other advanced solid tumors, as well as multiple programs in research and preclinical development.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/blueprint-medicines-to-present-on-blu-285-and-blu-554-at-upcoming-scientific-conferences-300429766.html

SOURCE Blueprint Medicines Corporation

Investor Relations: Kristin Williams, Blueprint Medicines Corporation, 617-714-6674, kwilliams@blueprintmedicines.com; Media Relations: Rachel Hutman, W20 Group, 301-801-5540, rhutman@wcgworld.com